| Literature DB >> 26671016 |
Martina Girardelli1, Serena Arrigo2, Arrigo Barabino3, Claudia Loganes4, Giuseppe Morreale5, Sergio Crovella6,7, Alberto Tommasini8, Anna Monica Bianco9.
Abstract
BACKGROUND: Aggressive course and resistance to treatments usually characterize very early onset inflammatory bowel disease (VEO-IBD). Some VEO-IBD cases are due to monogenic immune defects and can benefit from hematopoietic stem cell transplantation (HSCT). CASEEntities:
Mesh:
Substances:
Year: 2015 PMID: 26671016 PMCID: PMC4678727 DOI: 10.1186/s12887-015-0522-5
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Summary of clinical features and treatments
| 1 month | 2 – 3 months | 11.5 months | 15 months | |
|---|---|---|---|---|
| Clinical features | High fever, | High fever | Intractable diarrhoea | Intractable diarrhoea, Vomit, |
| Hepatomegaly, | Bloody and mucous diarrhoea | |||
| Recurrent fever | Recurrent fever | |||
| Splenomegaly | Failure to thrive | Skin rash | ||
| Mild splenomegaly | Mild hepato-splenomegaly | |||
| Haematological values | WBC 25.000/μl | WBC: 5.140/μl | WBC: 31.440/μl | WBC: 18.400/μl |
| (N 38 %) | (N29%) | (N 55 %) | (N 62 %) | |
| CRP: 14,3 mg/L | CRP: 21 mg/L | CRP: 107 mg/L | CRP: 99 mg/L | |
| AST: 219 U/L | AST: 47 U/L | |||
| ALT: 327 U/L | ALT: 41 U/L | |||
| LDH 2300 U/L | Triglycerides: 2,39 mmol/L | |||
| Triglycerides: 3,08 mmol/L | Ferritin: 1.651 ng/ml | |||
| Ferritin: 18.000 ng/ml | ||||
| IgA: 0,54 g/L | ||||
| IgG: 5,67 g/L | ||||
| IgM: 0,74 g/L | ||||
| hypoalbumiemia | ||||
| Specialist investigations | Bone marrow smear: negative | Colonoscopy: inflammatory colitis with erosions and aphthae and increased cell apoptosis | Colonoscopy: Crohn’s-like colitis | |
| EGDS normal | ||||
| CMV negative in mucosa | ||||
| Virology | Blood CMV: 435.800 copies/ml | Blood CMV: negative | ||
| Immunological evaluations | Normal Degranulation Assay | DHR test normal | ||
| Genetic evaluations | PRF1, SAP, STXBP2 wild type | FOXP3: wild type | MVK: wild type | IL10, IL10RA, L10RB: wild type |
| XIAP: mutate | ||||
| Therapeutic interventions | Glucocorticoids, ganciclovir | Intravenous glucocorticoids, tacrolimus, | Glucocorticoids, Azathioprine, Adalimumab | Glucocorticoids, Adalimumab, |
| TPN | ||||
| TPN | TPN | Antibiotics | ||
| Surgical intervention | none | none | Colectomy | HSCT |
DHR dihydrorhodamine
TPN total parenteral nutrition
HSCT hematopoietic stem cell transplantation
CRP C Reactive Protein: normal values below 10 mg/L also the EGDS acronimous should be added in the legenEGDS Esophagogastroduodenoscopy
Fig. 1Image of colonoscopy investigation. In the pictures is possible to appreciate the colonoscopy features of the patient, in particular the erosions and apthae.
Fig. 2Electropherogram and functional test of XIAP mutation. a The Figure shows electopherograms of the mutation (c.1021_1022delAA) in exon 4 of XIAP in genomic DNA of patient, mother (heterozygous) and control (wild type). b Scheme of the protein structure of XIAP: BIR 1, 2, 3 and RING domains are shown. Black arrow indicates the localization of the mutation found in our patient. The mutation results in the substitution of the wild-type amino acids NIHLTHSLE with the mutant amino acids YSFNSFT until the stop codon and in the truncation of the protein at 347 amino acid of the 497 wild type protein. c Detection of the XIAP protein by flow cytometry on patient, his mother and in two healthy donors (male age related with patient and female controls age related with mother). The intracellular staining was performed with two different anti-human XIAP antibodies that recognize the N-terminal domain (amino acids 1-202) or the C-terminal domain (amino acid 268–426), respectively in the left and in the right side. The XIAP expression was evaluated on the CD45+ CD3+ cell gate. Grey area in the dashed line represents staining with secondary antibody alone. d NOD signalling pathway assay was performed testing patient, mother and age matched controls PBMCs unstimulated (US) or treated with IL-1β and MDP. The integrity of the pathway was measured using an IL-8 ELISA. PBMCs from our Crohn’s like patient were unable to induce the production of IL-8 after MDP stimulation, compared with wild-type controls and his mother, who carries in heterozygous the same mutation. The histograms report the mean of the values obtained by two different experiments.
Fig. 3HSCT drug treatments. The figure illustrates the conditioning regimen administered to the patient before the HSCT and the combined drugs used for the prevention of graft-versus-host disease.